Plaque psoriasis is a chronic, inflammatory, immune-mediated skin disorder that negatively impacts a patient's quality of life, both physically and psychologically 1, 2 In individuals with a genetic predisposition, environmental factors (eg physical and psychological stress) may trigger the initiation of psoriasis, beginning with the activation of dendritic cells (Figure 1) 1, 3 Topical treatments containing corticosteroids and vitamin D analogues target key steps in psoriasis pathogenesis and are essential, well-established first-line treatments for patients with mild-to-moderate psoriasis 4, 5 Here we discuss recent data showing the anti-inflammatory and immunomodulatory mechanisms underlying the efficacy of fixed-dose combination therapy versus topical steroidal monotherapy, and explore developments in topical drug delivery and the clinical relevance of these data TNF-α IL-12 TNF-α and IFN-γ IL-17 and IL-22 Cytokines, chemokines and AMPs IL-23 Type 1 T-cell differentiation and activation Keratinocyte hyperproliferation and abnormal differentiation Psoriatic plaque formation Dendritic cell activation Type 17 T-cell differentiation and activation Figure 1. Key steps in the psoriasis pathogenesis loop Arrows indicate pro-inflammatory mediator release. AMP, antimicrobial peptide; IL, interleukin; IFN, interferon; TNF, tumour necrosis factor
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Plaque psoriasis is a chronic, inflammatory, immune-mediated skin disorder that negatively impacts a patient's quality of life, both physically and psychologically 1, 2 In individuals with a genetic predisposition, environmental factors (eg physical and psychological stress) may trigger the initiation of psoriasis, beginning with the activation of dendritic cells (Figure 1) 1, 3 Topical treatments containing corticosteroids and vitamin D analogues target key steps in psoriasis pathogenesis and are essential, well-established first-line treatments for patients with mild-to-moderate psoriasis 4, 5 Here we discuss recent data showing the anti-inflammatory and immunomodulatory mechanisms underlying the efficacy of fixed-dose combination therapy versus topical steroidal monotherapy, and explore developments in topical drug delivery and the clinical relevance of these data 
Corticosteroid and vitamin D analogue combination treatment addresses therapeutic goals, resulting in increased effectiveness versus monotherapy
The treatment goal is to clear the psoriatic plaques by inhibiting the underlying inflammation via immunomodulation (rather than immunosuppression), thereby normalizing skin homeostasis, keratinocyte proliferation and differentiation Both corticosteroids and vitamin D analogues inhibit pro-inflammatory mediator release ( Figure 1 ) from dendritic cells, Type 1 and 17 (cytotoxic and helper) T-cells, and keratinocytes. [6] [7] [8] [9] Vitamin D analogues exert normalizing effects on the hyperproliferation and abnormal differentiation of keratinocytes and also have immunomodulatory effects 6, 10 Recent preclinical data show that fixed-dose combination treatment provides significantly increased inhibition of pro-inflammatory cytokines compared with monotherapies ( Figure 2 ) 11 The effect of fixed-dose combination therapy on cellular targets in psoriasis pathophysiology is summarized in Figure 3a -d
Corticosteroid and vitamin D analogue combination topical treatment may provide long-term management of psoriasis
Upon clearance of psoriatic plaques and normalization of skin homeostasis, the therapeutic objective shifts to the maintenance of a relapse-free state as psoriatic inflammation tends to recur in previously affected skin locations 12, 13 -This may be caused by the expression of inflammatory cytokines upon reactivation of immune cells present in the apparently normalized, plaque-free skin after treatment 12, 13 New data indicate that combination treatment is able to induce regulatory T-cells, as well as counteract the activation and differentiation of cytotoxic T-cells, more effectively than corticosteroids alone ( Figure 3e 
Figure 2. Combination treatment in vitro is significantly more effective than monotherapies in inhibiting cytokines released from key cells involved in psoriasis pathogenesis
Levels of pro-inflammatory (IL-23, IL-17A and IL-8) and immunomodulatory (IL-10) cytokines released by DCs, T-cells, and KCs are expressed as percentage of vehicle-treated control (100%). 11 Treatment was applied before DC activation, after (IL-17A) and before (IL-10) Th-cell differentiation, and on stimulated KCs. 11 *Combination treatment also led to TNF-α inhibition (both P<0.001); † Similar results were found for the inhibition of IL 
Clinical benefits of corticosteroid and vitamin D analogue fixed-dose combination treatment
Corticosteroids and vitamin D analogues are directed at different targets in psoriasis pathogenesis. Their complementary and additive effects observed in preclinical data have translated into clinically effective fixed-dose combination therapies, as supported by randomized, double-blind, controlled clinical studies 14, 15 For example, fixed-dose combination calcipotriol (Cal)/betamethasone dipropionate (BD) aerosol foam was significantly more efficacious in improving mean modified Psoriasis Area and Severity Index (mPASI; excluding the head, which was not treated) score than the individual active ingredients after 4 weeks (P<0.001 versus both Cal foam and BD foam) 14
Combination therapy attenuates side effects associated with their individual monotherapies
Long-term continuous use of topical corticosteroids and vitamin D analogue monotherapy is associated with increased risk of skin atrophy and perilesional skin irritation, respectively ( Table 1 ) 5, 9, 16 -Recent studies in cultured skin cells demonstrated that the addition of Cal reduces early signs of betamethasone-induced skin atrophy by modulating key extracellular matrix components 17 -A 52-week clinical study demonstrated that daily treatment with Cal/BD ointment significantly reduced the overall number of adverse events -particularly burning, itching, and erythema of skin -compared with vitamin D analogue monotherapy (Cal ointment, 50 µg/g) 18 
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Challenges of drug delivery in topical formulations
Poor penetration of active ingredients into the skin can result in low, or lack of, clinical efficacy
The rate-limiting step for most topical treatments is the concentration of active ingredients dissolved in the vehicle One potential method of enhancing the rate of skin penetration is to increase the concentration of active ingredients dissolved in the applied product beyond the normal solubility limit, ie create a supersaturated solution A recent study with Cal/BD aerosol foam demonstrated that a stable supersaturated environment was created and maintained for clinically relevant time periods (at least 26 hours in the laboratory setting) 21 -This state was created after rapid evaporation of the propellants during application and may explain the observed increase in bioavailability of Cal/BD aerosol foam versus Cal/BD ointment 21
An innovative drug delivery formulation results in improved efficacy
A number of studies have demonstrated the superior efficacy of Cal/BD aerosol foam compared with traditional formulations such as ointments, gels, and lotions ( Table 2 ) 15, [22] [23] [24] The increased efficacy of Cal/BD aerosol foam is also associated with a similar safety profile, as demonstrated in a pooled safety analysis comparing fixed-dose combination Cal/BD aerosol foam with BD foam, Cal foam, Cal/BD ointment, and vehicles (foam and ointment) 25 
Innovation in topical therapy for psoriasis with corticosteroid and vitamin D analogue combination
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